The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that the reported results for the period (fiscal 2022 ended September 30, 2022) do not represent the business actually running today. The call is about Q4 FY2022 results. Management discusses many developments: pipeline progress, partnerships, Royalty Pharma deal, 20 in '25 program, etc. They emphasize clarity, progress, and that the company has changed. They mention that they have made progress on many fronts, with data expected soon, and that they have monetized royalties. They describe the period as highly productive but also point to things that have already been done after the period? Let's check. The call is on November 28, 2022, reporting fiscal year ended September 30, 2022. They announced the Royalty Pharma deal on November 9, 2022, which is after the period end. They mention that they expect milestone payments, data readouts, etc. They also say "we are gaining clearer understanding" etc. They talk about "20 in '25" as a plan for 2025. They emphasize that the company is building toward something. But does management convey that the reported period's numbers are stale relative to the operating present? They do mention the Royalty Pharma deal that brought in $250 million after the period, and they talk about pro forma cash. But that's a financing event, not an operating change. They also talk about pipeline progress, but the pipeline was already in progress during the period. The key question: Do they indicate that the business as it stands today is ahead of the business as it appears in the reported period? They mention that they have 12 drug candidates in clinical trials, and plan for 20 by 2025, but that's future. They mention that they have made clarity on Phase 3 designs, etc. But is there a repeated and substantial indication that the reported numbers reflect a company that has already been left behind? The call is a standard earnings call with results and outlook. They discuss financial results, then pipeline updates. They don't say "our reported results don't reflect what we are doing now." They do mention the Royalty Pharma deal that closed after the period, but that's a financing transaction that affects cash, not the underlying business. They also mention that they expect to report data soon. But that's typical forward-looking.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.